BI's Pradaxa antidote gets Breakthrough label

Share this article:

Boehringer Ingelheim announced today that its experimental antidote, designed to stop the bleeding for blood thinner agent Pradaxa, has received a Breakthrough Therapy designation from the FDA—making it the first antidote of its kind for this new class of anticoagulants.

BI recently settled 4,000 Pradaxa lawsuits for $650 million. The lawsuits centered on claims that there was no antidote to prevent bleeding-related deaths. FDA stated in November 2012, however, that the bleeding rates associated with Pradaxa were no higher than with warfarin.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.